Cesca Therapeutics Granted Third U.S. Patent Relating to Its Proprietary SurgWerks™ Platform

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the third of a family of patent applications related to its proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). The patent (numbered 9,439,930) protects key components of Cesca’s SurgWerks™ technology platform, relating to cell compositions & methods, designed for the rapid delivery of autologous regenerative cell therapies in a point-of-care environment.

“This patent covers critical methods for the rapid infusion of autologous bone marrow derived stem & progenitor cells, integral steps in our proprietary SurgWerks™ platform based treatment technique,” said Dalip Sethi, Ph.D., Cesca’s Director of Clinical Research. “Our growing portfolio of SurgWerks™ platform patents underpins our approach to the treatment of cardiovascular diseases with rapid, point-of-care procedures.”

Cesca has more than 30 issued patents covering its market leading technology for the concentration and cryogenic storage of umbilical cord blood derived stem & progenitor cells. With its expanding portfolio of intellectual property covering key components of the SurgWerks™ platform, the Company seeks to bring the same level of innovation to autologous, bone marrow derived stem cell treatments for cardiovascular and orthopedic disorders at the patient’s bedside.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:

• The SurgWerks™ System (in development) - a proprietary system comprised of the SurgWerks™ Processing Platform, including devices and analytics, and indication-specific SurgWerks™ Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.
• The CellWerks™ System (in development) - a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.
• The AutoXpress® System (AXP®) - a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.
• The MarrowXpress™ System (MXP™) - a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.
• The BioArchive® System - an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
• Manual bag sets for use in the processing and cryogenic storage of cord blood.

Forward-Looking Statements and Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release includes statements of future expectations and other forward-looking statements that are within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current views and assumptions, speak only as of the date hereof and are subject to change.  Forward-looking statements can often be identified by words such as “anticipates,” “belief,” “intend,” “may,” “could,” “would,” “potential,” “continue,” and similar expressions and include, but are not limited to, statements regarding research, development and commercialization of the SurgWerks™ system, patent applications and patent grants. These forward-looking statements are not guarantees of future results and are subject to known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially and adversely from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by these forward-looking statements is set forth under the caption "Risk Factors" in our Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, and in other reports filed with the Securities and Exchange Commission from time to time, and you should also consider each of those factors when evaluating the forward-looking statements. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

Company Contact: Cesca Therapeutics Inc.
[e-mail]

Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
[e-mail] / [e-mail]